|
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. |
|
|
Research Funding - Abbvie; Acerta Pharma/AstraZeneca; Bayer; Dr. Reddy's Laboratories; Janssen; Merck; Pfizer; Roche; Takeda |
Travel, Accommodations, Expenses - Abbvie; Jazz Pharmaceuticals; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - CITI BioPharma; Lilly; Omeros; Targeted Oncology |
Consulting or Advisory Role - CITI BioPharma |
Speakers' Bureau - CITI BioPharma; Lilly |
Research Funding - Abbvie; Astellas Pharma; Kronos Bio; Merck |
|
|
Consulting or Advisory Role - AstraZeneca (I); Genentech (I); MorphoSys; Seagen |
Speakers' Bureau - BeiGene |
Research Funding - ADC Therapeutics; Genentech; Karyopharm Therapeutics |
Expert Testimony - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Research Funding - BeiGene; Boryung; Dong-A Socio; Kyowa Kirin; Roche; Sanofi |
|
|
Consulting or Advisory Role - Takeda |
Speakers' Bureau - Abbvie; Roche; Takeda |
|
|
Consulting or Advisory Role - Epizyme |
Research Funding - BeiGene; Bristol-Myers Squibb; Celgene; TG Therapeutics |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca; MSD; Roche |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER |
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bayer; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda |
|
|
|
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Consulting or Advisory Role - Abbvie; Novartis; Takeda |